^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    betifisolimab (MSB2311)

    i
    Other names: MSB2311, MSB-2311, MSB 2311
    Associations

    News

    Trials
    Company:
    Transcenta
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    MSB2311-CSP-002t: A Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Completed, Suzhou Transcenta Therapeutics Co., Ltd. | Recruiting --> Completed | N=60 --> 42
    Trial completion • Enrollment change • Metastases
    |
    betifisolimab (MSB2311)
    11ms
    A Phase I Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Completed, Suzhou Transcenta Therapeutics Co., Ltd. | N=19 --> 42
    Enrollment change • Metastases
    |
    betifisolimab (MSB2311)
    over1year
    Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma. (PubMed, Cancer Immunol Immunother)
    One partial response was also observed among 6 patients with lymphoma. MSB2311 demonstrated a manageable safety profile and promising antitumor activity in patients with advanced solid tumors and lymphomas.
    P1 data • Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR • PD-L1 overexpression
    |
    betifisolimab (MSB2311)